Zacks: Brokerages Expect Antares Pharma Inc (NASDAQ:ATRS) Will Announce Quarterly Sales of $26.36 Million
Equities research analysts expect that Antares Pharma Inc (NASDAQ:ATRS) will report $26.36 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Antares Pharma’s earnings, with the highest sales estimate coming in at $27.30 million and the lowest estimate coming in at $24.60 million. Antares Pharma posted sales of $17.87 million in the same quarter last year, which suggests a positive year-over-year growth rate of 47.5%. The business is expected to issue its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Antares Pharma will report full-year sales of $108.05 million for the current fiscal year, with estimates ranging from $106.20 million to $109.20 million. For the next year, analysts anticipate that the firm will post sales of $155.99 million, with estimates ranging from $140.70 million to $165.47 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The firm had revenue of $28.43 million during the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%.
Shares of NASDAQ:ATRS traded up $0.12 during trading on Monday, reaching $3.48. 902,768 shares of the company traded hands, compared to its average volume of 1,006,463. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $567.46 million, a price-to-earnings ratio of -87.00 and a beta of 0.90. The business’s fifty day moving average is $3.23 and its 200-day moving average is $3.11. Antares Pharma has a 52-week low of $2.53 and a 52-week high of $3.96.
Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its holdings in shares of Antares Pharma by 54,541.8% during the first quarter. BNP Paribas Arbitrage SA now owns 30,053 shares of the specialty pharmaceutical company’s stock valued at $91,000 after acquiring an additional 29,998 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Antares Pharma during the first quarter valued at approximately $123,000. Fosun International Ltd raised its holdings in shares of Antares Pharma by 36.8% during the second quarter. Fosun International Ltd now owns 809,378 shares of the specialty pharmaceutical company’s stock valued at $2,574,000 after acquiring an additional 217,670 shares in the last quarter. AE Wealth Management LLC bought a new position in shares of Antares Pharma during the second quarter valued at approximately $98,000. Finally, Bank of America Corp DE raised its holdings in shares of Antares Pharma by 112.6% during the fourth quarter. Bank of America Corp DE now owns 101,544 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 53,772 shares in the last quarter. Institutional investors own 38.76% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Article: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.